Cargando…

The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke

BACKGROUND: Reactive astrogliosis is one of the significantly pathological features in ischemic stroke accompanied with changes in gene expression, morphology, and proliferation. KCa3.1 was involved in TGF-β-induced astrogliosis in vitro and also contributed to astrogliosis-mediated neuroinflammatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Mengni, Wei, Tianjiao, Wang, Yanxia, Lu, Qin, Chen, Gaoxian, Gao, Xiaoling, Geller, Herbert M., Chen, Hongzhuan, Yu, Zhihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644250/
https://www.ncbi.nlm.nih.gov/pubmed/29037241
http://dx.doi.org/10.1186/s12974-017-0973-8
_version_ 1783271699720962048
author Yi, Mengni
Wei, Tianjiao
Wang, Yanxia
Lu, Qin
Chen, Gaoxian
Gao, Xiaoling
Geller, Herbert M.
Chen, Hongzhuan
Yu, Zhihua
author_facet Yi, Mengni
Wei, Tianjiao
Wang, Yanxia
Lu, Qin
Chen, Gaoxian
Gao, Xiaoling
Geller, Herbert M.
Chen, Hongzhuan
Yu, Zhihua
author_sort Yi, Mengni
collection PubMed
description BACKGROUND: Reactive astrogliosis is one of the significantly pathological features in ischemic stroke accompanied with changes in gene expression, morphology, and proliferation. KCa3.1 was involved in TGF-β-induced astrogliosis in vitro and also contributed to astrogliosis-mediated neuroinflammation in neurodegeneration disease. METHODS: Wild type mice and KCa3.1(−/−) mice were subjected to permanent middle cerebral artery occlusion (pMCAO) to evaluate the infarct areas by 2,3,5-triphenyltetrazolium hydrochloride staining and neurological deficit. KCa3.1 channels expression and cell localization in the brain of pMCAO mice model were measured by immunoblotting and immunostaining. Glia activation and neuron loss was measured by immunostaining. DiBAC4 (3) and Fluo-4AM were used to measure membrane potential and cytosolic Ca(2+) level in oxygen-glucose deprivation induced reactive astrocytes in vitro. RESULTS: Immunohistochemistry on pMCAO mice infarcts showed strong upregulation of KCa3.1 immunoreactivity in reactive astrogliosis. KCa3.1(−/−) mice exhibited significantly smaller infarct areas on pMCAO and improved neurological deficit. Both activated gliosis and neuronal loss were attenuated in KCa3.1(−/−) pMCAO mice. In the primary cultured astrocytes, the expressions of KCa3.1 and TRPV4 were increased associated with upregulation of astrogliosis marker GFAP induced by oxygen-glucose deprivation. The activation of KCa3.1 hyperpolarized membrane potential and, by promoting the driving force for calcium, induced calcium entry through TRPV4, a cation channel of the transient receptor potential family. Double-labeled staining showed that KCa3.1 and TRPV4 channels co-localized in astrocytes. Blockade of KCa3.1 or TRPV4 inhibited the phenotype switch of reactive astrogliosis. CONCLUSIONS: Our data suggested that KCa3.1 inhibition might represent a promising therapeutic strategy for ischemia stroke. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-017-0973-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5644250
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56442502017-10-26 The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke Yi, Mengni Wei, Tianjiao Wang, Yanxia Lu, Qin Chen, Gaoxian Gao, Xiaoling Geller, Herbert M. Chen, Hongzhuan Yu, Zhihua J Neuroinflammation Research BACKGROUND: Reactive astrogliosis is one of the significantly pathological features in ischemic stroke accompanied with changes in gene expression, morphology, and proliferation. KCa3.1 was involved in TGF-β-induced astrogliosis in vitro and also contributed to astrogliosis-mediated neuroinflammation in neurodegeneration disease. METHODS: Wild type mice and KCa3.1(−/−) mice were subjected to permanent middle cerebral artery occlusion (pMCAO) to evaluate the infarct areas by 2,3,5-triphenyltetrazolium hydrochloride staining and neurological deficit. KCa3.1 channels expression and cell localization in the brain of pMCAO mice model were measured by immunoblotting and immunostaining. Glia activation and neuron loss was measured by immunostaining. DiBAC4 (3) and Fluo-4AM were used to measure membrane potential and cytosolic Ca(2+) level in oxygen-glucose deprivation induced reactive astrocytes in vitro. RESULTS: Immunohistochemistry on pMCAO mice infarcts showed strong upregulation of KCa3.1 immunoreactivity in reactive astrogliosis. KCa3.1(−/−) mice exhibited significantly smaller infarct areas on pMCAO and improved neurological deficit. Both activated gliosis and neuronal loss were attenuated in KCa3.1(−/−) pMCAO mice. In the primary cultured astrocytes, the expressions of KCa3.1 and TRPV4 were increased associated with upregulation of astrogliosis marker GFAP induced by oxygen-glucose deprivation. The activation of KCa3.1 hyperpolarized membrane potential and, by promoting the driving force for calcium, induced calcium entry through TRPV4, a cation channel of the transient receptor potential family. Double-labeled staining showed that KCa3.1 and TRPV4 channels co-localized in astrocytes. Blockade of KCa3.1 or TRPV4 inhibited the phenotype switch of reactive astrogliosis. CONCLUSIONS: Our data suggested that KCa3.1 inhibition might represent a promising therapeutic strategy for ischemia stroke. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-017-0973-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-16 /pmc/articles/PMC5644250/ /pubmed/29037241 http://dx.doi.org/10.1186/s12974-017-0973-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yi, Mengni
Wei, Tianjiao
Wang, Yanxia
Lu, Qin
Chen, Gaoxian
Gao, Xiaoling
Geller, Herbert M.
Chen, Hongzhuan
Yu, Zhihua
The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke
title The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke
title_full The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke
title_fullStr The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke
title_full_unstemmed The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke
title_short The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke
title_sort potassium channel kca3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644250/
https://www.ncbi.nlm.nih.gov/pubmed/29037241
http://dx.doi.org/10.1186/s12974-017-0973-8
work_keys_str_mv AT yimengni thepotassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT weitianjiao thepotassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT wangyanxia thepotassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT luqin thepotassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT chengaoxian thepotassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT gaoxiaoling thepotassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT gellerherbertm thepotassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT chenhongzhuan thepotassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT yuzhihua thepotassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT yimengni potassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT weitianjiao potassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT wangyanxia potassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT luqin potassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT chengaoxian potassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT gaoxiaoling potassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT gellerherbertm potassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT chenhongzhuan potassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke
AT yuzhihua potassiumchannelkca31constitutesapharmacologicaltargetforastrogliosisassociatedwithischemiastroke